Politically tied loan request awaits state panel's decision
The board on Wednesday delayed a decision on the REDI loan application, however, until after CoAxis Energy Company can provide additional information to the Governor's Office of Economic Development that the board has requested.
The board operates as the decision-making arm of GOED.
CoAxis is a liquid natural gas supplier and system designer. Its president is Scott Stern. He was GOED commissioner during the latter years of the Daugaard administration and is president of family-owned Stern Oil Company, based in Freeman.
Cheyenne River Reservation authorities investigating 2 deaths
Among others listed on the CoAxis website's leadership page is Dennis Daugaard, who served as South Dakota governor from 2011 through 2018.
Daugaard appointed Stern in 2016 as GOED commissioner. Stern stepped down in November 2018 as Daugaard's time as governor came to a close.
A business record on file at the South Dakota Secretary of State office shows that Stern established CoAxis in 2019, the year after he had returned to the private sector.
The CoAxis vice president is Trent Arlint. He is married to Republican Rep. Amber Arlint. Stern is her father.
Two of the state board's members, chair Jeff Erickson of Sioux Falls and Joy Nelson of Watertown, recused themselves from the discussion during the teleconference on Wednesday. Erickson said they serve on the board of directors for a bank that may be participating.
Erickson, Nelson and Daugaard are directors for American Bank & Trust. Erickson and Daugaard have also been involved with Standard Trust, a Sioux Falls-based investment company.
Gov. Larry Rhoden appointed Daugaard's son-in-law, Tony Venhuizen, as lieutenant governor earlier this year.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Epoch Times
18 minutes ago
- Epoch Times
The Hidden Math That Makes Some Australians Poorer for Working Harder
AD It may seem counterintuitive, but working longer hours can make you less money, the e61 Institute says. A pile of bills in Brisbane, Australia, on Oct. 30, 2013. AAP Image/Dan Peled 8/13/2025 | Updated: 8/13/2025 Not so long ago, working harder was thought to guarantee you were better off. Rex Widerstrom is a New Zealand-based reporter with over 40 years of experience in media, including radio and print. He is currently a presenter for Hutt Radio. Author's Selected Articles
Business Upturn
21 minutes ago
- Business Upturn
Indoco Remedies gets USFDA nod for generic Rivaroxaban tablets; eyes growth in US Market
Mumbai-based Indoco Remedies Ltd. has secured final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) to market Rivaroxaban Tablets USP in strengths of 2.5 mg, 10 mg, 15 mg, and 20 mg. The product is the generic equivalent of Janssen Pharmaceuticals' blockbuster anticoagulant, Xarelto, and will be manufactured at Indoco's Verna, Goa facility. The approved Rivaroxaban tablets are bioequivalent and therapeutically equivalent to Xarelto and are indicated for the treatment of venous thromboembolism (VTE). This approval marks another milestone in Indoco's push into the US generics market, one of the most lucrative pharmaceutical markets globally. Commenting on the development, Indoco Remedies' Managing Director Aditi Panandikar said, 'Besides reflecting the capability of Indoco Remedies to deliver products of high-quality standards, this development also provides impetus to our growth aspirations in an important market such as the US.' Indoco Remedies is a fully integrated, research-driven pharmaceutical company with a global footprint, generating over 106 million prescriptions annually in India alone. The company operates 11 manufacturing facilities — seven for finished dosage forms (FDFs) and four for active pharmaceutical ingredients (APIs) — all of which are approved by top global regulatory agencies including the USFDA and UK-MHRA. With a turnover of $180 million and a workforce of more than 6,000 employees, Indoco is known for popular domestic brands such as Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, and Cital. Internationally, the company partners with large generics players to expand its market reach across multiple geographies. The latest USFDA approval strengthens Indoco's product portfolio in the regulated market and could open up significant revenue opportunities as Rivaroxaban continues to be a widely prescribed oral anticoagulant in the US. Disclaimer: This news article is for informational purposes only and does not constitute investment advice. Investors should consult a qualified financial advisor before making investment decisions. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Fox News
29 minutes ago
- Fox News
Appeals court allows Arkansas' first-in-the-nation ban on gender transition care for minors to be enforced
A federal appeals court on Tuesday upheld an Arkansas law prohibiting doctors from providing gender transition medical treatment to minors, reversing a lower court decision that blocked the first-in-the-nation law. The 8th U.S. Circuit Court of Appeals ruled 8-2 on Tuesday to overturn a lower court decision, now allowing the state to enforce the law. The appeals court cited the U.S. Supreme Court decision in June upholding a similar ban in Tennessee, in which the nation's highest court ruled that the law was constitutional and did not discriminate against transgender people. Referencing the Supreme Court's decision, the appeals court agreed with Arkansas Attorney General Tim Griffin, a Republican, that the law did not violate transgender minors' equal protection rights under the U.S. Constitution. "I applaud the court's decision and am pleased that children in Arkansas will be protected from experimental procedures," Griffin said in a statement following the ruling. Arkansas Republican Gov. Sarah Huckabee Sanders wrote on social media that the ruling "is a win for common sense -- and for our kids." Arkansas became the first U.S. state to ban transgender treatments such as puberty blockers, hormones and surgery for minors in 2021, when the Republican-led legislature passed the ban after they overruled the veto of then-GOP Gov. Asa Hutchinson. Four families of transgender children and two doctors challenged the law, arguing the Save Adolescents From Experimentation (SAFE) Act violated parents' due process rights under the U.S. Constitution's Fourteenth Amendment. Writing the majority opinion, U.S. Circuit Judge Duane Benton said parents have never had a right to obtain medical treatment for their children that a state government had banned. The judge also wrote that the lower court's decision, in which U.S. District Judge Jay Moody ruled in 2023 that the law discriminates against transgender people and poses "immediate and irreparable harm" to transgender children, conflicts with the Supreme Court's decision in the Tennessee case. The law was also previously blocked from taking effect in 2021. U.S. Circuit Judge Jane Kelly, meanwhile, wrote in the dissent that there is a "startling lack of evidence connecting Arkansas' ban on gender-affirming care with its purported goal of protecting children." The American Civil Liberties Union and the American Civil Liberties Union of Arkansas were among the groups representing the plaintiffs. "This is a tragically unjust result for transgender Arkansans, their doctors, and their families," Holly Dickson, executive director of the ACLU of Arkansas, said in a statement. "The state had every opportunity and failed at every turn to prove that this law helps children; in fact, this is a dangerous law that harms children," she continued. "The law has already had a profound impact on families across Arkansas who all deserve a fundamental right to do what is best for their children. As we and our clients consider our next steps, we want transgender Arkansans to know they are far from alone and we remain as determined as ever to secure their right to safety, dignity, and equal access to the health care they need." The ruling on Tuesday comes after the 10th U.S. Circuit Court of Appeals ruled unanimously last week that a similar ban in Oklahoma is constitutional, also relying upon the Supreme Court's decision on the Tennessee law.
